➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Boehringer Ingelheim
Harvard Business School
McKinsey
Medtronic

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,005,020

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,005,020
Title: Bioresorbable compositions for implantable prostheses
Abstract:Crosslinked compositions formed from a water-insoluble copolymer are disclosed. These compositions are copolymers having a bioresorbable region, a hydrophilic region and at least two crosslinkable functional groups per polymer chain. These compositions are able to form hydrogels in aqueous environments when crosslinked. These hydrogels are good sealants for implantable prostheses when in contact with an aqueous environment. In addition, such hydrogels can be used as delivery vehicles for therapeutic agents.
Inventor(s): Loomis; Gary L. (Morristown, NJ)
Assignee: Meadox Medicals, Inc. (Oakland, NJ)
Application Number:09/145,588
Patent Claims:1. A medical device having on at least one surface thereof a bioresorbable coating composition, said composition comprising a hydrogel formed from the crosslinking of a polymer comprising the reaction of (i) a bioresorbable region; (ii) a hydrophilic region; (iii) a plurality of crosslinkable functional groups; and (iv) a crosslinking agent.

2. The medical device of claim 1 formed from an implantable material.

3. The medical device of claim 2, wherein said implantable material is selected from the group consisting of polymeric compositions, non-polymeric compositions and combinations thereof.

4. The medical device of claim 3, wherein said implantable material is further selected from the group of olefinic polymeric compositions consisting of polyethylene, polypropylene, polyvinyl chloride, polytetrafluoroethylene, fluorinated ethylene propylene copolymer, polyvinyl acetate, polystyrene, poly(ethylene terephthalate), polyurethane, polyurea, silicone rubbers, polyamides, polycarbonates, polyaldehydes, natural rubbers, polyether-ester copolymers, styrene-butadiene copolymers and combinations thereof.

5. The medical device of claim 3, wherein said implantable material is further selected from the group of non-polymeric compositions consisting of ceramics, metals, inorganic glasses, pyrolytic carbon and combinations thereof.

6. The medical device of claim 1, wherein said device is an endoprosthesis.

7. The medical device of claim 6, wherein said endoprosthesis is selected from the group consisting of grafts, stents and graft-stent devices.

8. The medical device of claim 2, selected from the group consisting of catheters, guide wires, trocars and introducer sheaths.

9. The medical device of claim 4, wherein said implantable material is a vascular or endovascular graft.

10. The medical device of claim 9, wherein said vascular or endovascular graft is a knitted, braided or woven textile.

11. The medical device of claim 2, wherein said implantable material is made from an extruded polymer.

12. A process for forming a hydrogel comprising:

a. combining (i) a bioresorbable region; (ii) a hydrophilic region; (iii) a plurality of crosslinkable functional groups per polymer chain; and (iv) a crosslinking agent to form an aqueous emulsion of a water-insoluble copolymer; and

b. activating said crosslinking agent.

13. The process of claim 12, wherein said crosslinkable functional groups are olefinically unsaturated.

14. The process of claim 12, wherein said crosslinking agent is a free radical initiator.

15. The process of claim 12, wherein said crosslinking agent is an azo or a peroxide composition.

16. The process of claim 12, wherein said crosslinking agent is thermally or photochemically activated.

17. A process for forming a medical device coated with a hydrogel comprising:

a. applying said hydrogel to said medical device, said hydrogel formed from an aqueous emulsion comprising a water-insoluble copolymer having (i) a bioresorbable region; (ii) a hydrophilic region; (iii) a plurality of crosslinkable functional groups per polymer chain; and (iv) a crosslinking agent; and

b. activating said crosslinking agent in a humid environment.

18. The process of claim 17, wherein said hydrogel is dehydrated.

19. The process of claim 17, wherein said hydrogel is maintained in a hydrated state.

20. The process of claim 17, further including adding a drug or bio-active agent to said emulsion.

21. The process of claim 20, wherein said drug bio-active agent is thrombo-resistant agents, antibiotic agents, anti-tumor agents, antiviral agents, anti-angiogenic agents, angiogenic agents, anti-inflammatory agents, cell cycle regulating agents, and chemically modified equivalents and combinations thereof their homologs, derivatives, fragments, pharmaceutical salts and combinations thereof.

22. The process of claim 20, wherein said drug or bio-active agent is selected from the group of thrombo-resistant agents consisting of heparin, heparin sulfate, hirudin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, urokinase, streptokinase, and chemically modified equivalents and combinations thereof their homologs, analogs, fragments, derivatives and pharmaceutical salts thereof.

23. The process of claim 20, wherein said drug or bio-active agent is selected from the group of antibiotic agents consisting of penicillins, cephalosporins, vancomycins, aminoglycosides, quinolones, polymyxins, erythromycins, tetracyclines, chloramphenicols, clindamycins, lincomycins, sulfonamides, and chemically modified equivalents and combinations thereof their homologs, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof.

24. The process of claim 20, wherein said drug or bio-active agent is selected from the group of anti-tumor agents consisting of paclitaxel, mechlorethamine, chlorambucil, cyclophosphamide, melphalan and ifosfamide, methotrexate, 6-mercaptopurine, 5-fluorouracil, cytarabine, vinblastine, vincristine, etoposide, doxorubicin, daunomycin, bleomycin, mitomycin, carmustine, lomustine, cisplatin, interferon, asparaginase, tamoxifen, flutamide, and chemically modified equivalents and combinations thereof their homologs, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof.

25. The process of claim 20, wherein said drug or bio-active agent is selected from the group of anti-viral agents consisting of amantadines, rimantadines, ribavirins, idoxuridines, vidarabines, trifluridines, acyclovirs, ganciclovirs, zidovudines, foscarnets, interferons, and chemically modified equivalents and combinations thereof their homologs, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof .

Details for Patent 6,005,020

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 001 1978-01-16   Start Trial Meadox Medicals, Inc. (Oakland, NJ) 2017-08-18 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16   Start Trial Meadox Medicals, Inc. (Oakland, NJ) 2017-08-18 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial Meadox Medicals, Inc. (Oakland, NJ) 2017-08-18 DISCN search
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Meadox Medicals, Inc. (Oakland, NJ) 2017-08-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
Harvard Business School
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.